These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 30714167)

  • 41. Epigenetic markers for noninvasive early detection of nasopharyngeal carcinoma by methylation-sensitive high resolution melting.
    Yang X; Dai W; Kwong DL; Szeto CY; Wong EH; Ng WT; Lee AW; Ngan RK; Yau CC; Tung SY; Lung ML
    Int J Cancer; 2015 Feb; 136(4):E127-35. PubMed ID: 25196065
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Longitudinal on-treatment circulating tumor DNA as a biomarker for real-time dynamic risk monitoring in cancer patients: The EP-SEASON study.
    Lv J; Xu LX; Li ZX; Lin L; Wu CF; Quan TQ; Zhen ZC; Li WF; Tang LL; Mao YP; Chen L; Guo R; Zhang LL; Ai XL; Wu SY; Hao MY; Wei D; Li JB; Ma J; Chen YP; Zhou GQ; Sun Y
    Cancer Cell; 2024 Aug; 42(8):1401-1414.e4. PubMed ID: 39059389
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical significance of plasma Epstein-Barr Virus DNA loads in a large cohort of Malaysian patients with nasopharyngeal carcinoma.
    Chai SJ; Pua KC; Saleh A; Yap YY; Lim PV; Subramaniam SK; Lum CL; Krishnan G; Mahiyuddin WR; ; Teo SH; Khoo AS; Yap LF
    J Clin Virol; 2012 Sep; 55(1):34-9. PubMed ID: 22739102
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Genome-Wide Analysis of 18 Epstein-Barr Viruses Isolated from Primary Nasopharyngeal Carcinoma Biopsy Specimens.
    Tu C; Zeng Z; Qi P; Li X; Yu Z; Guo C; Xiong F; Xiang B; Zhou M; Gong Z; Liao Q; Yu J; He Y; Zhang W; Li X; Li Y; Li G; Xiong W
    J Virol; 2017 Sep; 91(17):. PubMed ID: 28637758
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Detection of cell free Epstein-Barr virus DNA in sera from patients with nasopharyngeal carcinoma.
    Hsiao JR; Jin YT; Tsai ST
    Cancer; 2002 Feb; 94(3):723-9. PubMed ID: 11857305
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel biomarkers of nasopharyngeal carcinoma metastasis risk identified by reverse phase protein array based tumor profiling with consideration of plasma Epstein-Barr virus DNA load.
    Xu T; Su B; Huang P; Wei W; Deng Y; Sehgal V; Wang D; Jiang J; Zhang G; Li A; Yang H; Claret FX
    Proteomics Clin Appl; 2017 May; 11(5-6):. PubMed ID: 27883284
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Different prognostic values of plasma Epstein-Barr virus DNA and maximal standardized uptake value of 18F-FDG PET/CT for nasopharyngeal carcinoma patients with recurrence.
    Shen T; Tang LQ; Luo DH; Chen QY; Li PJ; Mai DM; Guo SS; Liu LT; Qian CN; Guo X; Zeng MS; Mo HY; Mai HQ
    PLoS One; 2015; 10(4):e0122756. PubMed ID: 25853677
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Serum EBV DNA as a biomarker in primary nasopharyngeal carcinoma of Indian origin.
    Krishna SM; James S; Kattoor J; Balaram P
    Jpn J Clin Oncol; 2004 Jun; 34(6):307-11. PubMed ID: 15333681
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma.
    Yao JJ; Zhou GQ; Wang YQ; Wang SY; Zhang WJ; Jin YN; Zhang F; Li L; Liu LZ; Cheng ZB; Ma J; Qi ZY; Sun Y
    Chin J Cancer; 2017 Dec; 36(1):98. PubMed ID: 29284539
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of Circulating Tumour Cells and Circulating Cell-Free Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Undergoing Radiotherapy.
    Vo JH; Nei WL; Hu M; Phyo WM; Wang F; Fong KW; Tan T; Soong YL; Cheah SL; Sommat K; Low H; Ling B; Ng J; Tan WL; Chan KS; Oon L; Ying JY; Tan MH
    Sci Rep; 2016 Dec; 6(1):13. PubMed ID: 28442757
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Plasma Epstein-Barr virus DNA screening followed by ¹⁸F-fluoro-2-deoxy-D-glucose positron emission tomography in detecting posttreatment failures of nasopharyngeal carcinoma.
    Wang WY; Twu CW; Lin WY; Jiang RS; Liang KL; Chen KW; Wu CT; Shih YT; Lin JC
    Cancer; 2011 Oct; 117(19):4452-9. PubMed ID: 21437892
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Circulating tumor cells: a valuable marker of poor prognosis for advanced nasopharyngeal carcinoma.
    Ou G; Xing S; Li J; Zhang L; Chen S
    Mol Med; 2019 Nov; 25(1):50. PubMed ID: 31729954
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA.
    Lo YM; Chan AT; Chan LY; Leung SF; Lam CW; Huang DP; Johnson PJ
    Cancer Res; 2000 Dec; 60(24):6878-81. PubMed ID: 11156384
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prognostic value of gross tumor regression and plasma Epstein Barr Virus DNA levels at the end of intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma.
    Liang SB; Zhang N; Chen DM; Yang XL; Chen BH; Zhao H; Lu RL; Chen Y; Fu LW
    Radiother Oncol; 2019 Mar; 132():223-229. PubMed ID: 30366725
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Laboratory markers of tumor burden in nasopharyngeal carcinoma: a comparison of viral load and serologic tests for Epstein-Barr virus.
    Fan H; Nicholls J; Chua D; Chan KH; Sham J; Lee S; Gulley ML
    Int J Cancer; 2004 Dec; 112(6):1036-41. PubMed ID: 15386346
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Assessment of detection assays of Epstein-Barr viral Rta-IgG, VCA-IgA, EA-IgA and Epstein-Barr viral DNA at different clinical stages in the diagnosis of nasopharyngeal carcinoma].
    Luo YL; Chen H; Peng SG; Lin JH; Huang PY
    Zhonghua Yi Xue Za Zhi; 2013 Nov; 93(44):3516-9. PubMed ID: 24521892
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Detection of Epstein-Barr virus DNA in serum or plasma for nasopharyngeal cancer: a meta-analysis.
    Liu Y; Fang Z; Liu L; Yang S; Zhang L
    Genet Test Mol Biomarkers; 2011; 15(7-8):495-502. PubMed ID: 21410354
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of Epstein-Barr virus DNA measurement in plasma in the clinical management of nasopharyngeal carcinoma in a low risk area.
    Kalpoe JS; Dekker PB; van Krieken JH; Baatenburg de Jong RJ; Kroes AC
    J Clin Pathol; 2006 May; 59(5):537-41. PubMed ID: 16489178
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Prognostic impact of plasma Epstein-Barr virus DNA concentration on distant metastasis in nasopharyngeal carcinoma].
    Hou X; Zhang L; Zhao C; Li S; Lu LX; Han F; Shao JY; Huang PY
    Ai Zheng; 2006 Jul; 25(7):785-92. PubMed ID: 16831265
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Epstein-Barr virus mir-bart1-5p detection via nasopharyngeal brush sampling is effective for diagnosing nasopharyngeal carcinoma.
    Zheng XH; Lu LX; Cui C; Chen MY; Li XZ; Jia WH
    Oncotarget; 2016 Jan; 7(4):4972-80. PubMed ID: 26701721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.